Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05320263
Other study ID # 2018_0105
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 19, 2022
Est. completion date July 2027

Study information

Verified date February 2023
Source Hopital Foch
Contact Arturo CONSOLI
Phone 0033146251955
Email a.consoli@hopital-foch.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Acute ischemic stroke (AIS) patients with basilar artery occlusion (BAO) present a devastating, life-threatening prognosis. Urgent recanalization with endovascular mechanical thrombectomy is routinely performed in patients with BAO although the level of evidence is lower than that in anterior circulation occlusions (randomization in this population versus medical treatment alone having been impossible in recent studies). Recently, a large retrospective study supports the interest of thrombectomy in this population . Speed and grade of the recanalisation have a major impact on clinical outcome. Favorable outcome at 90 days is strongly associated with the successful recanalization status at the end of the endovascular procedure (OR=4.57, 95%CI=1.24-16.87, P=0.023). First pass effect has been shown to be a strong marker of efficacy of endovascular procedure with significant correlation with clinical outcome. Thrombectomy with Stent retrievers dramatically changed the prognosis of anterior circulation large vessel occlusion strokes and currently used in BAO patients (posterior circulation). Contact aspiration (CA) is currently used in anterior large vessel occlusions (COMPASS trial, Lancet 2019), with similar rates of recanalization and favorable outcomes (Boulanger M, 2019), as well as in BAO patients . However, the benefit of CA compared to SR for the treatment of BAO remains under debate with the superiority of first line CA compared to SR or no difference. Available data are based on retrospective studies with no data from RCT. In this context, a randomized controlled trial is needed to assess the benefit of CA versus SR.


Recruitment information / eligibility

Status Recruiting
Enrollment 480
Est. completion date July 2027
Est. primary completion date July 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Age = 18 years - AIS with BAO on non-invasive imaging (CT or MRI) - Eligible for thrombectomy : groin puncture undergone within 24 hours of first symptoms or of last time the patient was seen normal - Being covered by a national health insurance - Informed consent obtained from the patients/his proxy or following an emergency procedure Exclusion Criteria: - Known or suspected pre-existing (chronic) large vessel stenosis / occlusion in the symptomatic territory (basilar artery) - Severe contrast medium allergy or absolute contraindication to use of iodinated products - Clinical history, past imaging or clinical judgment suggesting intracranial stenosis of the basilar artery - Pregnancy (urine or serum beta HCG test for women of child-bearing potential) - Person deprived of liberty - Patient benefiting from a legal protection (guardianship or curatorship)

Study Design


Intervention

Procedure:
Contact aspiration Thrombectomy
The contact aspiration approach is performed, as in standard care, using a long sheath positioned in the distal cervical vasculature using an exchange technique. A large bore balloon guide catheter as to be placed into the cervical ICA. The microcatheter is then advanced close to the thrombus and the large-bore aspiration catheter is advanced as close to the proximal aspect of the thrombus as possible. A control superselective angiogram may be used to document the extent of occlusion and thrombus. After a 3 min waiting period, the large-bore aspiration catheter is connected to a continuous aspiration from the dedicated aspiration pump while simultaneously advancing the aspiration catheter up to the face of the thrombus. through the long sheath positioned in the cervical vasculature.
Stent retriever thrombectomy
The technique used should be in accordance with the device IFU. A large bore access guide catheter possible is recommended. A suitable delivery microcatheter is navigated over a microwire across the occlusion. A control superselective angiogram may be used to document the extent of occlusion and thrombus. The stent is left in place according to the internal practice of each participating center before the withdrawal. Any CE-marked stent retriever device is then deployed across the occlusion. A minimum of 3 attempts with SR should be performed. A revascularization score will be recorded after each device attempt.

Locations

Country Name City State
France Chu Bordeaux Bordeaux
France CHU Caen Caen
France CHU Limoges Limoges
France CHU Montpellier Montpellier
France Chru Nancy Nancy
France Chu Nantes Nantes
France APHP - Pitié Salpêtrière Paris
France Fondation Adolphe de Rothschild Paris
France CHU de Reims Reims
France CHU Rennes Rennes
France Hôpital FOCH Suresnes
France CHU de Tours Tours

Sponsors (1)

Lead Sponsor Collaborator
Hopital Foch

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of first pass effect (FPE) defined by complete reperfusion after first device pass The definition of FPE: single pass/use of the device, (2) complete revascularization of the large vessel occlusion and its downstream territory (mTICI 3), and (3) no use of rescue therapy 24 hours
Secondary Rate of complete reperfusion after first-line thrombectomy strategy and at the end of endovascular procedure mTICI (modified Thrombolysis In Cerebral Infarction ) score equals to 3 after the first line thrombectomy and at the end of endovascular.
mTICI score is evaluated between 0-3 : 0 a complete obstruction of the artery and 3 indicates a complete reperfusion
24 hours
Secondary Rate of successful reperfusion (mTICI 2b/2c/3) after first-line thrombectomy strategy and at the end of endovascular procedure mTICI score is evaluated between 0 to 3. Rate of patients with mTICI score equals to 2b/2c/3 after first-line thrombectomy strategy and at the end of endovascular procedure will be evaluated. 24 hours
Secondary Rate of near to complete reperfusion (mTICI 2c/3) after first-line thrombectomy strategy and at the end of endovascular procedure 24 hours
Secondary Rate of Arterial Occlusive Lesion (AOL) recanalization score III after first-line thrombectomy strategy and at the end of endovascular procedure AOL recanalization score is evaluated between 0 to 3 :
0 indicates no recanalization of the primary occlusive lesion
3 indicates complete recanalization of the primary occlusive lesion with any distal flow
24 hours
Secondary Groin puncture time to successful reperfusion time (evaluated in minutes) 360 minutes
Secondary Modified Rankin Score (mRS) at 3 and 12 months mRS is evaluated between 0 to 6. A score of 0 indicates that there is no disability and a score of 6 indicates death. 12 months
Secondary Rate of good functional outcome at 90-day and at one year defined by a mRS 0-3 or equal to pre-stroke mRS (Modified Rankin Score) 12 months
Secondary Quality of life at 90 days and 12 months assessed by EuroQol 5D-5L scale EuroQol 5D-5L comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. 12 months
Secondary All cause of mortality at 90-day and 12 months 12 months
Secondary 24-hours change in NIHSS (National Institutes of Health Stroke Scale) from baseline defined as the difference between NIHSS score at 24 hours and NIHSS score at admission. NIHSS (National Institutes of Health Stroke Scale) score is evaluated between 0-42 0 is normal and 42 maximal gravity 24 hours
Secondary Subgroups analysis : Age (=70 vs. >70 years) 24 hours
Secondary Subgroups analysis :Baseline NIHSS=10 vs NIHSS<10 (18) 24 hours
Secondary Subgroups analysis : Volume of infarct area assessed by pc-ASPECTS (=7 vs. >7) A pc-ASPECTS score of 10 indicates absence of visible ischemic changes in the posterior circulation, and pc-ASPECTS score of 0 indicates ischemic changes in the midbrain, pons, and bilateral thalami, posterior circulation territories, and cerebellar hemispheres 24 hours
Secondary Subgroups analysis : Time from admission of patient in hospital to randomization (= 300 vs. > 300 minutes) 360 minutes
Secondary Subgroups analysis: Baseline site of thrombi on vascular imaging (Top of the basilar artery vs other adjudicated by the core lab) 24 hours
Secondary Subgroups analysis: Prior use of IV alteplase (yes vs. no) 24 hours
Secondary Subgroups analysis : Collateral status (good versus poor, as adjudicated by the core lab on initial angiogram) with a 0-3 scale Collateral circulation is estimated by angiography with a 0-3 scale. The collateral status will be categorized as poor collaterals (scores 0-1) and good collaterals (scores 2-3) 24 hours
Secondary Incidence of any intracerebral hemorrhage (ICH), parenchymal hematoma (PH), symptomatic ICH on brain imaging (Magnetic resonance imaging MRI or CT (computed tomography) scan) at 24±12h after thrombectomy (according to ECASS3 classification) ECASS III (European Cooperative Acute Stroke Study) classification :
Hemorrhage infarction type 1 (HI1)
Hemorrhage infarction type 2 (HI2)
Parenchymal hematoma type 1 (PH1)
Parenchymal hematoma type 2 (PH2)
24 hours
Secondary Incidence of procedure-related complications defined as arterial perforation, arterial dissection, embolization in a new territory (ENT) and subarachnoid haemorrhage hours
Secondary Cost-effectiveness analysis at 12 months Incremental cost-effectiveness ratio (ICER, cost per quality-adjusted life year [QALY]), of Contact Aspiration (CA) first-line thrombectomy compared to standard first-line SR thrombectomy in treatment of AIS due to BAO, from a collective perspective and with a 12-months' time horizon. 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT01717755 - Basilar Artery International Cooperation Study N/A
Recruiting NCT06101667 - Efficacy and Safety of Endovascular Recanalization for Acute Basilar Artery Occlusion With Extended Time Window (ANGEL-BAO) N/A
Recruiting NCT05615038 - A Comparison of Contact Aspiration Versus Stent Retriever for Acute Basilar Artery Occlusion N/A
Recruiting NCT05105633 - Extending the Time Window for Tenecteplase by Recanalization of Basilar Artery Occlusion in Posterior Circulation Stroke Phase 2/Phase 3
Not yet recruiting NCT04177615 - Randomized Assessment of Rapid Endovascular Treatment in Basilar Artery Occlusion Stroke in 115 Hospital N/A
Recruiting NCT05827042 - Endovascular Thrombectomy Alone Versus Intravenous Thrombolysis Plus Thrombectomy on Acute Basilar Artery Occlusion Phase 3
Recruiting NCT05701956 - Intravenous Tenecteplase Plus EVT Versus EVT Alone on 4.5 to 24 Hours After Basilar Artery Occlusion Phase 3
Active, not recruiting NCT02737189 - Basilar Artery Occlusion Chinese Endovascular Trial N/A
Not yet recruiting NCT05580822 - Additive Effects of Intra-arterial Tenecteplase for Successful Thrombectomy Due to Acute Basilar Artery Occlusion Phase 2
Completed NCT04751708 - Endovascular Treatment for Acute Basilar Artery Occlusion N/A
Recruiting NCT05512910 - Minocycline for Acute Ischemic Stroke Undergoing Endovascular Treatment Due to Basilar Artery Occlusion (MIST-B) Phase 4
Recruiting NCT05402878 - OUTCOME AND SAFETY OF RECANALIZATION TREATMENTS IN ISCHEMIC STROKE DUE TO ACUTE BASILAR ARTERY OCCLUSION
Recruiting NCT05631847 - Direct Endovascular Treatment Versus Bridging Treatment In Basilar Artery Occlusive Stroke N/A